Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBAvalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of….
New prototype therapy may repair IPF lung scarring by …
WEBby Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. $15K award goes to researcher for work into IPF disease risk factors September 20, 2024; Learning to live with both sleep apnea and pulmonary fibrosis September 17, 2024; Navigating emotional ups and downs on my IPF journey September 17, 2024; Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF September 13, 2024; A new twist in my journey: Familial idiopathic ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Pulmonary Fibrosis Study Shows Enzyme Can Help Reverse Scarring
WEBby José Lopes, PhD February 19, 2018. An enzyme can start a chain of events that leads to cells involved in tissue scarring reversing their fibrosis-generating activity, British and American researchers have discovered. The study dealt with the enzyme’s effect on myofibroblasts — cells involved in wound healing and inflammatory response.
What Is Pulmonary Fibrosis?
WEBSep 24, 2021 · Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung conditions collectively known as interstitial lung diseases (ILDs), many of which are known to cause progressive fibrosis.. Types and causes of PF. In most cases, the exact cause of lung scarring is ...
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
WEBAug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, and conditions such as chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH) can impact disease prognosis.
High Levels of IL-35 May Slow PF Progression, Early Study Finds
WEBNov 8, 2021 · by Margarida Maia, PhD November 8, 2021. A signaling molecule called interleukin 35 (IL-35) is at unusually high levels in lung tissues from mice and in people with pulmonary fibrosis (PF), and seems to play a role in slowing disease progression, a study found. These findings indicate that IL-35 might be a new therapeutic target for a disease ...
Pulmonary Fibrosis Lung Transplant
WEBAccording to the Scientific Registry of Transplant Recipients, 98.4% of patients survive the first year, 74.8% of patients survive three years, and 61.2% survive five years. The study “ Lung transplantation for idiopathic pulmonary fibrosis,” by researchers from the Department of Thoracic and Cardiovascular Surgery at Cleveland Clinic ...
NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
WEBJul 19, 2022 · Most idiopathic pulmonary fibrosis (IPF) patients treated with NP-120 (ifenprodil) in a 12-week clinical trial saw their lung function improve or stabilize, and most also experienced an easing in coughing, according to top-line data announced by the therapy’s developer, Algernon Pharmaceuticals.